SpliceBio secured a $135 million Series B round to advance its dual AAV gene therapy candidate SB-007 for Stargardt disease despite a challenging funding environment. Meanwhile, National Resilience, a manufacturing startup with over $2 billion raised, announced partial site closures amid a biopharma slowdown. Recursion Pharmaceuticals similarly cut workforce by 20%, reflecting a broader industry trend of recalibration following early rapid expansions.